Loading... (0%)
About liver disease
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more
Elafibranor phase 3 study in NASH with fibrosis is currently recruiting patients all around the world.
LEARN MORE
The NASH Education Program: An initiative by GENFIT
LEARN MORE

Press releases
  • GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
    11/22/2017
  • GENFIT completes a €180 million offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022
    10/17/2017
  • GENFIT: Third quarter 2017 financial information
    10/11/2017
  • GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor
    09/20/2017
  • GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH
    06/23/2017
Events